EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Proteomic profiling reveals treatment-dependent inflammatory signatures and identifies biomarkers of refractory age-related macular degeneration

Chiara M Eandi, Angelica Borgo, Eva de Oliveira Figueiredo, Diego de Haro, Daniel E Kaufmann, Raphael Roduit

Frontiers in Pharmacology · 16.06.2026 · 17

DOI: 10.3389/fphar.2026.1793714 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 16.06.2026. Verfasst von Chiara M Eandi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, University of Lausanne, Jules-Gonin Eye Hospital, Lausanne, Switzerland. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Age-related macular degeneration (AMD) is a severe eye disease that affects the macula, the central area of the retina. Current treatment consists of intravitreal injections of vascular endothelial growth factor (VEGF) inhibitors. However, some patients remain refractory to treatment even after maximal anti-VEGF dosage. We longitudinally analyzed angiogenic and inflammatory biomarkers in the aqueous humor (AH) of these patients.

Objectives

1) To confirm the presence of angiogenic and inflammatory biomarkers before (in the naive state) and after two anti-VEGF injections; and 2) to characterize the inflammatory response according to the type of anti-VEGF used (ranibizumab, aflibercept, brolucizumab, or faricimab).

Methods

AH samples were collected from two groups of patients: 35 patients with AMD and 17 control patients with no retinopathy. Eleven of the 35 patients with AMD were characterized as refractory (rAMD) after long-term anti-VEGF treatment. Multiplex and proximity extension assays (PEA) were performed on these samples to define their inflammatory profiles. Free VEGFA was detected using an additional AlphaLISA VEGFA assay.

Results

Several inflammatory molecules are upregulated in AMD, while a smaller subset is downregulated in rAMD, indicating that these could serve as markers of a refractory state. In contrast, no differences were observed in the biomarkers previously reported as increased in rAMD after long term treatment. These findings suggest that anti-VEGF treatment induces the expression of angiogenic and inflammatory biomarkers. Analysis of the inflammatory response following the injection of different anti-VEGF agents revealed exacerbated inflammation in patients treated with brolucizumab, whereas ranibizumab caused the lowest inflammatory response. In addition, we compared three different assays to assess AH VEGFA, but only the AlphaLISA assay could detect free VEGFA.

Conclusion

Our results indicate that anti-VEGFA therapy shapes AMD-associated inflammation; therefore, the choice of anti-VEGFA therapy remains important in reducing secondary inflammatory effects. Furthermore, the detection of free VEGF is dependent on the assay used.

Schlagwörter

Stichwörter der Autor:innen

age-related macular degeneration (AMD)angiogenic factorsanti-VEGF drugsinflammationmultiplexingolink-PEArefractory AMD (rAMD)

Autor:innen und Institutionen

  • Department of Ophthalmology, University of Lausanne, Jules-Gonin Eye Hospital, Lausanne, Switzerland.
  • Department of Surgical Sciences, University of Torino, Turin, Italy.
  • Division of Infectious Diseases, Department of Medicine, Lausanne University Hospital (CHUV) and Université de Lausanne, Lausanne, Switzerland.

Zitieren

APA

Eandi, C. M., Borgo, A., de Oliveira Figueiredo, E., de Haro, D., Kaufmann, D. E., & Roduit, R. (2026). Proteomic profiling reveals treatment-dependent inflammatory signatures and identifies biomarkers of refractory age-related macular degeneration. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1793714

Vancouver

Eandi CM, Borgo A, de Oliveira Figueiredo E, de Haro D, Kaufmann DE, Roduit R. Proteomic profiling reveals treatment-dependent inflammatory signatures and identifies biomarkers of refractory age-related macular degeneration. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1793714

BibTeX
@article{Eandi2026,
  author = {Eandi, Chiara M and Borgo, Angelica and de Oliveira Figueiredo, Eva and de Haro, Diego and Kaufmann, Daniel E and Roduit, Raphael},
  title = {Proteomic profiling reveals treatment-dependent inflammatory signatures and identifies biomarkers of refractory age-related macular degeneration},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1793714}
}
Kostenlos starten →